Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,001 to 1,020 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Vitamins vs Placebo: Hematocrit ≤24% With Transfusion | 40 of 4,954 59 of 4,927 | -0.4 points -0.8 to 0.0 | 9,881 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Postpartum Pulmonary Edema | 3 of 4,951 10 of 4,926 | -0.1 points -0.3 to 0.0 | 9,877 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Severe COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline | 0 of 6,581 1 of 3,285 | -0.0 points -0.2 to 0.0 | 9,866 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
| S-268019-b vs Placebo: Number of Participants With First Occurrence of SARS-CoV-2 RT-PCR-Positive Symptomatic COVID-19 in the Initial Vaccination Period Regardless of Serostatus or PCR Status at Baseline | 479 of 6,579 324 of 3,285 | -2.6 points -3.8 to -1.4 | 9,864 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
| Vitamins vs Placebo: Premature Rupture of Membranes | 124 of 4,934 129 of 4,923 | -0.1 points -0.7 to 0.5 | 9,857 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - MedDRA | 43 of 4,905 65 of 4,904 | -0.4 points -0.9 to -0.0 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - MedDRA | 17 of 4,905 8 of 4,904 | 0.2 points -0.0 to 0.4 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Cardiac Deaths - ISC | 31 of 4,905 12 of 4,904 | 0.4 points 0.1 to 0.7 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - MedDRA | 13 of 4,905 21 of 4,904 | -0.2 points -0.4 to 0.1 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Number of Participants With Suicide Attempts (Fatal and Non-fatal) - ISC | 68 of 4,905 76 of 4,904 | -0.2 points -0.6 to 0.3 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - MedDRA | 34 of 4,905 32 of 4,904 | 0.0 points -0.3 to 0.4 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Number of Participants With Discontinuation of Treatment for Any Reason Other Than Study Closure | 3,136 of 4,905 2,597 of 4,904 | 11.0 points 9.0 to 12.9 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Number of Participants With Hospitalisations, Excluding Hospitalisations Related to the Primary Psychiatric Disease | 174 of 4,905 149 of 4,904 | 0.5 points -0.2 to 1.2 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Second Primary Outcome: Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation | 10 of 4,905 6 of 4,904 | 0.1 points -0.1 to 0.3 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Other Than Cardiac Deaths and Completed Suicides - ISC | 19 of 4,905 28 of 4,904 | -0.2 points -0.5 to 0.1 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: Cause-specific Mortality: Number of Participants With Completed Suicides - ISC | 14 of 4,905 21 of 4,904 | -0.1 points -0.4 to 0.1 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Sertindole vs Risperidone: serious adverse events | 266 of 4,905 217 of 4,904 | 1.0 points 0.1 to 1.9 | 9,809 | NCT00856583 Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use |
| Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing Cardiovascular Death Included in the POE | 223 of 4,906 229 of 4,898 | -0.1 points -1.0 to 0.7 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
| Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Nonfatal MI Included in the POE | 200 of 4,906 159 of 4,898 | 0.8 points 0.1 to 1.6 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
| Randomized Sibutramine vs Randomized Placebo: Risk of Experiencing a Nonfatal Stroke Included in the POE | 127 of 4,906 95 of 4,898 | 0.6 points 0.1 to 1.2 | 9,804 | NCT00234832 A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=51
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00135707-e8bbd0ff",
"title": "Vitamins vs Placebo: Hematocrit ≤24% With Transfusion",
"summary": "40 of 4954 against 59 of 4927; risk difference -0.4 points, 95% interval -0.8 to 0.0; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
"record": "/library/comparisons/NCT00135707-e8bbd0ff",
"nct_id": "NCT00135707",
"kind": "outcome",
"participants": 9881,
"risk_difference": {
"value": -0.0039005491479598906,
"lower": -0.007951271735701978,
"upper": 0.0000487861100292317
},
"group_1": "40 of 4,954",
"group_2": "59 of 4,927",
"difference": "-0.4 points",
"interval": "-0.8 to 0.0",
"trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
},
{
"id": "NCT00135707-fef46187",
"title": "Vitamins vs Placebo: Postpartum Pulmonary Edema",
"summary": "3 of 4951 against 10 of 4926; risk difference -0.1 points, 95% interval -0.3 to 0.0; NCT00135707, Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)",
"record": "/library/comparisons/NCT00135707-fef46187",
"nct_id": "NCT00135707",
"kind": "outcome",
"participants": 9877,
"risk_difference": {
"value": -0.0014241064666783605,
"lower": -0.0031734441539366474,
"upper": 0.00007189114431334809
},
"group_1": "3 of 4,951",
"group_2": "10 of 4,926",
"difference": "-0.1 points",
"interval": "-0.3 to 0.0",
"trial_title": "Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=52",
"request_id": "mUpkDq1NyV4Q7ZF2"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant